{"prompt": "['CONFIDENTIAL', 'Verrica Pharmaceuticals Inc.', 'VP-102', 'Clinical Protocol: VP-102-103', 'Subjects will be given a 24-hour phone number to call the investigator or a clinical', 'research team member in the event of questions or AEs. Evaluations will also be', 'provided by the subject or parent/guardian using the Patient Evaluation of Response to', 'Investigational Treatment (PERIT) form the following day after Study drug', 'application. Parents will also be asked to take and send photos via text or e-mail to the', 'study team for assessment during the 24-hour follow-up call. All observed AEs, local', 'skin reactions and parent-reported AEs will be recorded.', 'Parents or guardians must provide informed consent, and pediatric subjects older than', '5 years must provide assent as required by the IRB before any study procedures are', 'conducted. Subjects must meet all study eligibility criteria through a complete review', 'of pertinent medical history, a symptom/sign evaluation, and limited physical', 'examination. Full inclusion/exclusion criteria are provided in Section 2.2.', '2.2', 'STUDY POPULATION', 'There will be up to 40 subjects enrolled with the goal of 16 completing all blood draws', 'in the exposure group. A maximum of 16 will be enrolled in the standard treatment', 'group. The additional 8 subjects may be used for replacement patients. Any subject in', 'the exposure group who does not complete all blood draws may continue to receive', 'treatment, but will be replaced. No more than 16 subjects will be considered as', 'completed Exposure group participants. At least 3 patients in the exposure group will', 'be from 2-5 years of age. Subjects will be considered enrolled when they have signed', 'informed consent and have received at least 1 treatment.', 'Eligibility will be established by the investigator on the basis of the inclusion and', 'exclusion criteria.', '2.2.1', 'Inclusion Criteria', 'To qualify for inclusion in this study, subjects must:', '1.', 'Be healthy subjects, ages 2 years and older.', '2.', \"Patients with 1-20 lesions may be enrolled and treated in the 'standard treatment' group\", 'but are not eligible for the exposure study OR', 'Page 27']['CONFIDENTIAL', 'Verrica Pharmaceuticals Inc.', 'VP-102', 'Clinical Protocol: VP-102-103', 'Patients with 21 or more lesions may only be enrolled in the \"exposure group\\' Subjects', 'participating in the Exposure group must have at least 21 lesions treated at Day 1 to', 'qualify.', '3.', 'Be otherwise medically healthy with no clinically significant medical history as', 'determined by the investigator. Patients exhibiting active Atopic Dermatitis may be', 'enrolled.', '4. Refrain from application of all topical agents including alcohol-based sanitary products', 'and sunscreens for a minimum of 4 hours before Study drug application. Topical agents', 'including alcohol-based sanitary products and sunscreens may be used after application', 'of the study drug so long as they are not applied to or near treated skin.', '5.', 'Refrain from swimming, bathing or prolonged immersion in water until the Study', 'drug is removed.', '6.', 'Have the ability or have a guardian able to follow study instructions and be likely to', 'complete all study requirements.', '7.', 'Provide assent in a manner approved by the institutional review board (IRB) and have', 'a parent/guardian provide written informed consent as evidenced by signature on IRB', 'approved assent/consent forms.', '8. Provide written authorization for use and disclosure of protected health information.', '9. Agree to allow photographs of all selected lesions to be taken and/or send photos via', \"text or email to the study team for assessment at 24 hours' post treatment. These images\", 'may be used on handouts in future trials, for training purposes, as part of the study data', 'and/or marketing package. Photographs will be de-identified to those outside the', 'research team. Effort will be made to ensure that no photos with identifiable features', 'are obtained.', 'Page 28']['CONFIDENTIAL', 'Verrica Pharmaceuticals Inc.', 'VP-102', 'Clinical Protocol: VP-102-103', '2.2.2', 'Exclusion Criteria', 'Candidates will be excluded from the study if they:', '1.', 'Are unable to cooperate with the requirements or visits of the study, as determined by', 'the investigator.', '2.', 'Have molluscum venereum (sexually transmitted molluscum).', '3.', 'Have active molluscum eczema.', '4. Are systemically immunosuppressed or are receiving treatments such as chemotherapy', 'or other non-topical immunosuppressive agents.', '5.', 'Have had any previous treatment of molluscum in the past 14 days including the use of', 'cantharidin, antivirals, retinoids, curettage or freezing of lesions. Additional treatments', 'should not be implemented during the course of the study.', '6.', 'Have history of illness or any dermatologic disorder, which, in the opinion of the', 'investigator will interfere with accurate counting of lesions or increase the risk of', 'adverse events.', '7.', 'History or presence of clinically significant medical, psychiatric, or emotional', 'condition or abnormality that in the opinion of the investigator would compromise the', 'safety of the subject or the quality of the data.', '8.', 'Have a history or presence of hypersensitivity or an idiosyncratic reaction to the Study', 'drug or related compounds, or drug product excipients (acetone, ethyl alcohol,', 'nitrocellulose, castor oil, camphor, gentian violet, and denatonium benzoate).', \"9. Have a condition or situation that may interfere significantly with the subject's\", 'participation in the study (e.g., patients who required hospitalization in the 2 months', 'prior to screening for an acute or chronic condition including alcohol or drug abuse),', 'at the discretion of the investigator.', 'Page 29']\n\n###\n\n", "completion": "END"}